Brief: Pharming Presents Positive Phase II Topline Data For Leniolisib
BRIEF-Pharming Presents Positive Phase II Topline Data For Leniolisib Oct 14 (Reuters) - Pharming Group N.V. PHAR.AS:
PRESENTS POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN GENETIC PIDS WITH IMMUNE DYSREGULATION AT ESID 2026
LENIOLISIB WELL-TOLERATED WITH BENEFITS IN IMMUNE DYSREGULATION MEASURES
MEAN SPLEEN VOLUME REDUCTION OF 26.4% IN PHASE II LENIOLISIB TRIAL
IMPROVEMENT IN LIVER STIFFNESS OBSERVED IN PHASE II LENIOLISIB TRIAL
MEAN LYMPH NODE LESION SIZE REDUCTION OF 33.7% IN PHASE II LENIOLISIB TRIAL
MEAN DLCO INCREASED BY 8.0% IN PHASE II LENIOLISIB TRIAL
ALL PHASE II LENIOLISIB STUDY COMPLETERS ENROLLED IN THREE-YEAR EXTENSION STUDY
LENIOLISIB WAS GENERALLY WELL-TOLERATED ACROSS ALL 4 GENOTYPES
TOPLINE RESULTS FROM SEPARATE PHASE II TRIAL IN CVID EXPECTED IN NOVEMBER
Source text: ID:nGNE6y1QPF
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))